• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Physiology >Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans.
【24h】

Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans.

机译：神经肽Y拮抗作用可减少人体反射性皮肤血管收缩。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Previous studies have provided evidence of a non-noradrenergic contributor to reflex cutaneous vasoconstriction in humans but did not identify the transmitter responsible. To test whether neuropeptide Y (NPY) has a role, in two series of experiments we slowly reduced whole body skin temperature (TSK) from 34.5 to 31.7 degrees C. In protocol 1, Ringer solution and the NPY receptor antagonist BIBP-3226 alone were delivered intradermally via microdialysis. In protocol 2, yohimbine plus propranolol (Yoh + Pro), Yoh + Pro in combination with BIBP-3226, and Ringer solution were delivered to antagonize locally the vasomotor effects of NPY and norepinephrine. Blood flow was measured by laser Doppler flowmetry (LDF). Mean arterial blood pressure (MAP) was monitored at the finger (Finapres). In protocol 1, cutaneous vascular conductance (CVC) fell by 45%, to 55.1 +/- 5.6% of baseline at control sites (P < 0.05). At BIBP-3226-treated sites, CVC fell by 34.1% to 65.9 +/- 5.0% (P < 0.05; P < 0.05 between sites). Inprotocol 2, during body cooling, CVC at control sites fell by 32.6%, to 67.4 +/- 4.3% of baseline; at sites treated with Yoh + Pro, CVC fell by 18.7%, to 81.3 +/- 4.4% of baseline (P < 0.05 vs. baseline; P < 0.05 vs. control) and did not fall significantly at sites treated with BIBP-3226 + Yoh + Pro (P > 0.05; P < 0.05 vs. other sites). After cooling, exogenous norepinephrine induced vasoconstriction at control sites (P < 0.05) but not at sites treated with Yoh + Pro + BIBP-3226 (P > 0.05). These results indicate that NPY participates in sympathetically mediated cutaneous vasoconstriction in humans during whole body cooling.
机译：先前的研究已经提供了人类体内反射性皮肤血管收缩的非去甲肾上腺素贡献者的证据，但并未确定负责的递质。为了测试神经肽Y（NPY）是否起作用，在两个系列的实验中，我们将全身皮肤温度（TSK）从34.5缓慢降低到31.7摄氏度。在方案1中，仅使用林格氏液和NPY受体拮抗剂BIBP-3226。通过微透析皮内递送。在方案2中，递送育亨宾加普萘洛尔（Yoh + Pro），Yoh + Pro与BIBP-3226组合以及林格溶液，以局部拮抗NPY和去甲肾上腺素的血管舒缩作用。通过激光多普勒血流仪（LDF）测量血流量。在手指（Finapres）处监测平均动脉血压（MAP）。在方案1中，对照部位的皮肤血管电导（CVC）下降了45％，降至基线的55.1 +/- 5.6％（P <0.05）。在经BIBP-3226处理的部位，CVC下降了34.1％，降至65.9 +/- 5.0％（部位间P <0.05;部位间P <0.05）。禁忌症2，在身体冷却期间，对照部位的CVC下降了32.6％，降至基线的67.4 +/- 4.3％;在用Yoh + Pro治疗的部位，CVC下降了18.7％，降至基线的81.3 +/- 4.4％（与基线相比，P <0.05;与对照相比，P <0.05），而在用BIBP-3226治疗的部位，CVC并未显着下降+ Yoh + Pro（与其他网站相比，P> 0.05; P <0.05）。冷却后，外源去甲肾上腺素在对照位点诱导血管收缩（P <0.05），但在Yoh + Pro + BIBP-3226处理的位点未诱导血管收缩（P> 0.05）。这些结果表明，NPY在全身冷却过程中参与了交感神经介导的皮肤血管收缩。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号